18 results
PRE 14A
AKRO
Akero Therapeutics Inc
16 Apr 24
Preliminary proxy
4:30pm
and Executive Vice President from March 2018 through September 2018. During his nearly 20-year tenure, he was responsible for the clinical development … January 2009 to June 2014. During his tenure at Pfizer Inc., Dr. Rolph also oversaw the Company’s FGF21 program. Dr. Rolph holds a B.Sc
8-K
EX-3.1
8ctarf1pab tg5dyq6
12 Mar 21
Amendments to Articles of Incorporation or Bylaws
5:25pm
DEF 14A
i3ed1dppo4t
27 Apr 20
Definitive proxy
7:30am
8-K
EX-3.2
lrr6mj2tn33mti8eu9
24 Jun 19
Amendments to Articles of Incorporation or Bylaws
4:17pm
424B4
42seg0430
20 Jun 19
Prospectus supplement with pricing info
5:20pm
S-1/A
qyyj6ns4jqq1ao6z2lf
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-10.9
nqxadv5f
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-10.10
caz9x 27mbmas
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-10.8
iwdljy
10 Jun 19
IPO registration (amended)
11:16am
S-1/A
EX-3.4
xeru fyme35z
10 Jun 19
IPO registration (amended)
11:16am
S-1
py4b54rwc wnl
24 May 19
IPO registration
4:18pm
DRS/A
pobqdtdz
30 Apr 19
Draft registration statement (amended)
12:00am
DRS/A
cc023xsx
19 Mar 19
Draft registration statement (amended)
12:00am
DRS
de5tmu37
17 Jan 19
Draft registration statement
12:00am
- Prev
- 1
- Next